Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Hennessey, Patrick T ^a   Ochs, Michael F ^a   Mydlarz, Wojciech W ^a   Hsueh, Wayne ^b   Cope, Leslie ^a   Yu, Wayne ^c   Califano, Joseph A ^a,d  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d GREATER BALTIMORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HYDROGEN SULFITE; SULFITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; MICROARRAY ANALYSIS; MOUSE; MOUTH MUCOSA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIMARY TUMOR; PROMOTER REGION; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; CLUSTER ANALYSIS; CPG ISLAND; DNA PROBE; DNA SEQUENCE; DRUG SCREENING; GENETICS; HEAD AND NECK TUMOR; METABOLISM; REPRODUCIBILITY; TUMOR CELL LINE;

MUS MUSCULUS;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CLUSTER ANALYSIS; CPG ISLANDS; DNA METHYLATION; DNA PROBES; HEAD AND NECK NEOPLASMS; HUMANS; MICE; PROMOTER REGIONS, GENETIC; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA; SULFITES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79957568722     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020584     Document Type: Article

References (32)

1. Jones PA, Baylin SB, (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
2. Jones PA, Laird PW, (1999) Cancer epigenetics comes of age. Nat Genet 21: 163-167.
3. Jones PA, Baylin SB, (2007) The epigenomics of cancer. Cell 128: 683-692.
4. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, et al. (2002) Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2: 485-495.
5. Kim MS, Yamashita K, Baek JH, Park HL, Carvalho AL, et al. (2006) N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res 66: 3409-3418.
6. Tokumaru Y, Yamashita K, Osada M, Nomoto S, Sun DI, et al. (2004) Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res 64: 5982-5987.
7. Smiraglia DJ, Rush LJ, Fruhwald MC, Dai Z, Held WA, et al. (2001) Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet 10: 1413-1419.
8. Kawai J, Hirose K, Fushiki S, Hirotsune S, Ozawa N, et al. (1994) Comparison of DNA Methylation Patterns among Mouse-Cell Lines by Restriction Landmark Genomic Scanning. Molecular and Cellular Biology 14: 7421-7427.
9. Grafodatskaya D, Choufani S, Ferreira JC, Butcher DT, Lou Y, et al. (2010) EBV transformation and cell culturing destabilizes DNA methylation in human lymphoblastoid cell lines. Genomics 95: 73-83.
10. Antequera F, Boyes J, Bird A, (1990) High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell 62: 503-514.
11. Suter CM, Norrie M, Ku SL, Cheong KF, Tomlinson I, et al. (2003) CpG island methylation is a common finding in colorectal cancer cell lines. British Journal of Cancer 88: 413-419.
12. Saferali A, Grundberg E, Berlivet S, Beauchemin H, Morcos L, et al. (2010) Cell culture-induced aberrant methylation of the imprinted IG DMR in human lymphoblastoid cell lines. Epigenetics 5: 50-60.
13. Kim MM, Glazer CA, Mambo E, Chatterjee A, Zhao M, et al. (2006) Head and neck cancer cell lines exhibit differential mitochondrial repair deficiency in response to 4NQO. Oral Oncol 42: 201-207.
14. Smyth GK, Michaud J, Scott HS, (2005) Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21: 2067-2075.
15. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
16. Saeed AI, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34: 374-378.
17. Li LC, Dahiya R, (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431.
18. Koizume S, Tachibana K, Sekiya T, Hirohashi S, Shiraishi M, (2002) Heterogeneity in the modification and involvement of chromatin components of the CpG island of the silenced human CDH1 gene in cancer cells. Nucleic Acids Res 30: 4770-4780.
19. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, et al. (2003) A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 63: 1114-1121.
20. Tan AC, Jimeno A, Lin SH, Wheelhouse J, Chan F, et al. (2009) Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol 3: 425-438.
21. Houshdaran S, Hawley S, Palmer C, Campan M, Olsen MN, et al. (2010) DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS One 5: e9359.
22. Milne AN, Sitarz R, Carvalho R, Polak MM, Ligtenberg M, et al. (2007) Molecular analysis of primary gastric cancer, corresponding xenografts, and 2 novel gastric carcinoma cell lines reveals novel alterations in gastric carcinogenesis. Hum Pathol 38: 903-913.
23. Chuang JC, Warner SL, Vollmer D, Vankayalapati H, Redkar S, et al. (2010) S110, a 5-Aza-2′-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther 9: 1443-1450.
24. TCGA (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
25. Fiebig HH, Maier A, Burger AM, (2004) Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 40: 802-820.
26. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, et al. (2006) An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12: 4652-4661.
27. Lock RB, Liem N, Farnsworth ML, Milross CG, Xue C, et al. (2002) The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 99: 4100-4108.
28. Stratton JA, Kucera PR, Rettenmaier MA, Dobashi K, Micha JP, et al. (1986) Accurate laboratory predictions of the clinical response of patients with advanced ovarian cancer to treatment with cyclophosphamide, doxorubicin, and cisplatin. Gynecol Oncol 25: 302-310.
29. Dong X, Guan J, English JC, Flint J, Yee J, et al. (2010) Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res 16: 1442-1451.
30. Merk J, Rolff J, Becker M, Leschber G, Fichtner I, (2009) Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur J Cardiothorac Surg 36: 454-459.
31. Dong X, Guan J, English JC, Flint J, Yee J, et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res 16: 1442-1451.
32. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, et al. (2008) Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 14: 6456-6468.